These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 14671165)

  • 1. An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men.
    Drake WM; Kendler DL; Rosen CJ; Orwoll ES
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5759-65. PubMed ID: 14671165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alendronate for the treatment of osteoporosis in men.
    Orwoll E; Ettinger M; Weiss S; Miller P; Kendler D; Graham J; Adami S; Weber K; Lorenc R; Pietschmann P; Vandormael K; Lombardi A
    N Engl J Med; 2000 Aug; 343(9):604-10. PubMed ID: 10979796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate.
    Watts NB; Jenkins DK; Visor JM; Casal DC; Geusens P
    Osteoporos Int; 2001; 12(4):279-88. PubMed ID: 11420777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
    Fink E; Cormier C; Steinmetz P; Kindermans C; Le Bouc Y; Souberbielle JC
    Osteoporos Int; 2000; 11(4):295-303. PubMed ID: 10928218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption.
    Anderson FH; Francis RM; Peaston RT; Wastell HJ
    J Bone Miner Res; 1997 Mar; 12(3):472-8. PubMed ID: 9076591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
    Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.
    Bauer DC; Garnero P; Hochberg MC; Santora A; Delmas P; Ewing SK; Black DM;
    J Bone Miner Res; 2006 Feb; 21(2):292-9. PubMed ID: 16418785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.
    Bauer DC; Black DM; Garnero P; Hochberg M; Ott S; Orloff J; Thompson DE; Ewing SK; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1250-8. PubMed ID: 15231011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex steroids and bone turnover markers in men with symptomatic vertebral fractures.
    Tuck SP; Scane AC; Fraser WD; Diver MJ; Eastell R; Francis RM
    Bone; 2008 Dec; 43(6):999-1005. PubMed ID: 18817902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
    Rittmaster RS; Bolognese M; Ettinger MP; Hanley DA; Hodsman AB; Kendler DL; Rosen CJ
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
    J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGF-I and testosterone levels as predictors of bone mineral density in healthy, community-dwelling men.
    Rucker D; Ezzat S; Diamandi A; Khosravi J; Hanley DA
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):491-9. PubMed ID: 15049965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
    Hochberg MC; Ross PD; Black D; Cummings SR; Genant HK; Nevitt MC; Barrett-Connor E; Musliner T; Thompson D
    Arthritis Rheum; 1999 Jun; 42(6):1246-54. PubMed ID: 10366118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.